Form 8-K - Current report:
SEC Accession No. 0000950170-25-028403
Filing Date
2025-02-27
Accepted
2025-02-27 08:40:08
Documents
15
Period of Report
2025-02-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jagx-20250226.htm   iXBRL 8-K 75855
2 EX-3.1 jagx-ex3_1.htm EX-3.1 55688
3 EX-4.1 jagx-ex4_1.htm EX-4.1 607928
4 EX-99.1 jagx-ex99_1.htm EX-99.1 34122
5 GRAPHIC img107817981_0.jpg GRAPHIC 37880
  Complete submission text file 0000950170-25-028403.txt   1043023

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT jagx-20250226.xsd EX-101.SCH 25864
17 EXTRACTED XBRL INSTANCE DOCUMENT jagx-20250226_htm.xml XML 4889
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 25673216
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)